ABBV-467 (12.5 mg/kg, i.v., once per week for 3 weeks) exhibits significant antitumor activity in t(4;14)-translocated multiple myeloma mouse models[1].
| Animal Model: | t(4;14) (chromosomal translocation between chromosome 4 and chromosome 14)-translocated high-risk multiple myeloma NOD-SCID mice[1] |
| Dosage: | 6.25 mg/kg and 12.5 mg/kg |
| Administration: | Intravenous injection (i.v.), once per week for 3 weeks |
| Result: | Resulted in a maximal tumor delay of 82% at 6.25 mg/kg and complete tumor regression at 12.5 mg/kg. |
